Business Wire1d
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Arrowhead says FDA accepts NDA for investigational plozasiran
Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...
TMCnet3d
Beacon Confirms Receipt and Reiterates Rejection of Unsolicited Proposal
Beacon (Nasdaq: BECN) (the "Company") today confirmed that it has previously received and rejected an unsolicited, non-binding proposal from QXO, Inc. (Nasdaq: QXO) to acquire all outstanding shares ...
Is LJP planning to contest Delhi polls? This is what Chirag Paswan says
“Lok Janshakti Party's (Ram Vilas) policy is to strengthen the (NDA) alliance and to contest elections on only those seats ...
manilatimes5d
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
Aquestive successfully completed a pre-Investigational New Drug meeting with the FDA in December 2024. The written response received from the FDA was supportive of continued development and Aquestive ...